

Supplementary table 1. Exacerbation and mortality after 18 months of follow-up in COPD patients with different smoke history.

Variables	Never smoker (n = 234)	Former smoker (n = 478)	Current smoker (n = 695)	P-value
Exacerbations, (Mean ± SD)	0.8 ± 1.5	0.9 ± 1.4	1.5 ± 1.9 ^{a, b}	0.008
Exacerbations, n (%)				0.006
0	178 (73.6)	327 (70.2)	438 (66.1) ^{a, b}	
1	28 (13.2)	63 (14.4)	108 (16.3)	
≥2	22 (13.2)	61 (15.4)	117 (17.6) ^{a, b}	
Hospitalizations, (Mean ± SD)	0.4 ± 1.0	0.4 ± 0.8	0.6 ± 1.2 ^{a, b}	0.045
Hospitalizations, n (%)				0.035
0	182 (79.8)	361 (78.8)	480 (73.2) ^{a, b}	
≥1	46 (20.2)	97 (21.2)	176 (26.8) ^{a, b}	
Mortality, n (%)	6 (2.6)	20 (4.2)	39 (5.6)	0.135

Notes: ^a Compared with the Never smoker group, *P* < 0.05; ^b Compared with the Former smoker group, *P* < 0.05.

Abbreviations: COPD, Chronic Obstructive Pulmonary Disease; SD, Standard Deviation.

Supplementary table 2. Exacerbation and mortality after 18 months of follow-up in COPD patients with different amounts of smoking (packs/year).

Variables	< 10 packs/year (n = 239)	≥ 10 packs/year (n = 1168)	P - value
Exacerbations, (Mean ± SD)	0.8 ± 1.5	0.7 ± 1.3	0.306
Exacerbations, n (%)			0.949
0	147 (62.8)	692 (62.5)	
1	39 (16.7)	194 (17.5)	
≥2	48 (20.5)	222 (20.0)	
Hospitalizations, (Mean ± SD)	0.4 ± 1.0	0.4 ± 0.8	0.753
Hospitalizations, n (%)			0.298
0	180 (76.9)	816 (73.6)	
≥1	54 (23.1)	292 (26.4)	
Mortality, n (%)	5 (2.5)	60 (5.1)	0.045

Note: COPD, Chronic Obstructive Pulmonary Disease; SD, Standard Deviation.

Supplementary table 3. The baseline characteristics of more symptomatic COPD patients who remained in the study and lost to follow-up.

Variables	More symptomatic patients		<i>P</i> - value
	A ₁ (n=1107)	A ₂ (n=281)	
Age (years), (Mean ± SD)	65.5 ± 8.0	65.6 ± 8.0	0.813
Sex, n (%)			
Male	988 (89.3)	250 (89.0)	
Female	119 (10.7)	31 (11.0)	
Education level, n (%)			0.158
Primary school	455 (41.1)	130 (46.3)	
Junior high school	428 (38.7)	88 (31.3)	
High school	173 (15.7)	49 (17.4)	
University	51 (4.6)	14 (5.0)	
BMI (kg/m ²)	22.3 ± 3.7	22.5 ± 3.7	
Smoke history, n (%)			0.290
Never smoker	187 (16.9)	53 (18.9)	
Former smoker	385 (34.8)	84 (29.9)	
Current smoker	535 (48.3)	144 (51.2)	
Smoking, (packs/year), (Mean ± SD)	37.5 ± 28.6	36.1 ± 26.7	0.433
Biofuel exposure, n (%)			0.493
Yes	440 (39.8)	118 (42.0)	
No	667 (60.2)	163 (58.0)	
Occupational exposure, n (%)			0.629
Yes	416 (37.6)	110 (39.1)	
No	691 (62.4)	171 (60.9)	
Pulmonary function, (Mean ± SD)			
FEV1	1.8 ± 0.5	1.2 ± 0.5	0.908
FEV1 %pred	48.6 ± 19.0	49.5 ± 19.1	0.480
FVC	2.6 ± 0.7	2.6 ± 0.7	0.439
FEV1/FVC	44.4 ± 12.2	44.7 ± 12.1	0.664
PEF	3.2 ± 1.4	3.1 ± 1.4	0.498
GOLD stages, n (%)			0.706
1	71 (6.4)	19 (6.8)	
2	408 (36.9)	110 (39.1)	
3	427 (38.6)	109 (38.8)	
4	201 (18.1)	43 (15.3)	
CAT, (Mean ± SD)	17.6 ± 5.4	17.3 ± 5.2	0.400
mMRC, (Mean ± SD)	2.3 ± 0.9	2.3 ± 0.9	0.885
CCQ, (Mean ± SD)	23.7 ± 6.5	23.2 ± 6.4	0.206
Treatments, n (%)			
LAMA	363 (32.8)	101 (35.9)	0.317
LABA + ICS	82 (7.4)	15 (5.3)	0.224
LAMA + LABA	24 (2.2)	3 (1.1)	0.233
LAMA + LABA + ICS	558 (50.4)	137 (48.8)	0.621

Oxygen therapy, n (%)			0.393
Yes	92 (8.3)	19 (6.8)	
No	1015 (91.7)	262 (93.2)	
Exacerbations in the past year, (Mean ± SD)	1.8 ± 3.3	1.9 ± 3.5	0.603
Hospitalizations in the past year, (Mean ± SD)	0.8 ± 1.5	0.7 ± 1.3	0.467

Notes: A₁: The COPD patients who remained in the study after 18 months of follow-up; A₂: The COPD patients who lost to follow-up.

Abbreviations: BMI, Body Mass Index; COPD, Chronic Obstructive Pulmonary Disease; CAT, COPD Assessment Test; CCQ, Clinical COPD Questionnaire; FEV₁, Forced Expiratory Volume in one second; FVC, Forced Vital Capacity; GOLD, Global Initiative for Chronic Obstructive Lung Disease; ICS, Inhaled Corticosteroid; LAMA, Long-Acting Muscarinic Antagonist; LABA, Long-Acting β₂-Agonist; mMRC, modified Medical Research Council; PEF, Peak Expiratory Flow; SD, Standard Deviation.